Dataset from A Dose Finding Study of GSK716155 Versus Placebo in the Treatment of Type 2 Diabetes Mellitus

This is a randomized, double-blind, placebo-controlled, multicenter, 4-parallel-group, dose ranging study evaluating the dose response, efficacy and safety of subcutaneously injected GSK716155 (albiglutide) in Japanese subjects with type 2 diabetes mellitus.

本研究为一项随机、双盲、安慰剂对照、多中心、四平行组剂量递增研究，旨在评估皮下注射GSK716155（阿必鲁肽，albiglutide）在2型糖尿病日本受试者中的量效反应、有效性及安全性。